Show news: from last 30 days (default), 60 days, 90 days, last visit or all

EMA adopts a positive opinion for Epidyolex

14th August 2019

The EMA has recommended that the EU grants a Marketing authorization (MA) for Epidyolex (cannabidiol) for the treatment of seizures associated with Lennox-Gastaut syndrome or Dravet syndrome in conjunction with clobazam for patients >2 years age. Epidyolex is an oral solution of cannabidiol 100mg/mL.

click here to view